Alluvi, previously BI 4744, presents a promising breakthrough in weight loss treatment. This dual stimulator targeting both GLP-1 and GIP targets demonstrates compelling efficacy in clinical studies, potentially https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/